# 510(k) Summary

# Submitted by:

Hyphen BioMed 95000 Neuville sur oise, France Phone # 01 34 40 65 10 Fax# 301 34 48 72 36

Contact Person: D. Jean Amiral, President & Scientific Director   
Summary prepared by: April $3 0 ^ { 1 1 }$ 2007   
Name of the Device: ZYMUTEST HIA IgG and ZYMUTEST HIA IgGAM   
Classification Name: Anti-Platelet Factor IV Complex Antibodies   
Regulation #: 864.7695   
Product Code: LCO/0545

Identification of Predicate device:

1. ASSERACHROM $\textcircled{8}$ HPIA Test Kit (Stago) PF4 ENHANCED Solid Phase ELISA (GTI)

# Predicate device 510 (k) number:

1. K003767   
2. K053559

# Description of the Device:

The ZYMUTEST HIA is solid phase enzyme linked immunosorbent assay (ELISA) designed to detect antibodies. These antibodies are found in some patients undergoing heparin therapy.

# Indication for use:

ZYMUTEST HIA IgG and IgGAM kits are designed as a solid phase enzymelinked immunosorbent assay (ELISA). These products are intended to be used as an in vitro diagnostics kit by Hematology, coagulation or other pathology laboratories to assist in screening patients samples for the presence of heparinassociated antibodies commonly found in patients with heparin induced thrombocytopenia or thrombosis (HIT).

# Substantial equivalence is based on comparison of characteristics to the predicate devices.

ZYMUTEST HIA test kit uses the same principle as the predicate devices ASSERACHROM Â®HPIA test kit and PF4 ENHANCED which are substantially equivalent in performance, intended use and technical principle.

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device (ZYMUTESTHIA IgG and IgGAM)</td><td rowspan=1 colspan=1>Predicate(ASSERACHROMHPIA)</td><td rowspan=1 colspan=1>Predicate(PF4Enhanced)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Determination of anti-heparin Platelet factor 4</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>SampleRequirement</td><td rowspan=1 colspan=1>Citrated human plasmaor Serum</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Design</td><td rowspan=1 colspan=1>Sandwich technique ofenzyme-linkedimmunosorbent assay(ELISA)</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr></table>

In addition, these products have the same indication for use and same scientific technology.

# Summary of performance Data:

Inter-lot reproducibility and comparison with predicate device

Zymutest IgGAM was compared with Asserachrom (predicate device). Total of 44 plasma samples were analyzed. This was an internal study.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Asserachrom</td><td rowspan=1 colspan=1>ZymutestIgGAM</td><td rowspan=1 colspan=1>%Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>93%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>88%</td></tr></table>

In clinical studies, Zymutest IgGAM was compared with Asserachrom for $\mathtt { n } = 2 4 3$ plasma samples.

<table><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Asserachrom</td></tr><tr><td rowspan=1 colspan=1>Site 1 &amp; 2</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ZymutestIgGAM</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>32</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>136</td></tr><tr><td rowspan=1 colspan=2>Agreement</td><td rowspan=1 colspan=1>76%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Co-positivity</td><td rowspan=1 colspan=1>64%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Co-negativity</td><td rowspan=1 colspan=1>81%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Sample Size</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1></td></tr></table>

In clinical studies, Zymutest IgGAM was compared with GTI PF4 Enhanced for $\mathtt { n } = 3 4 5$ plasma samples.

<table><tr><td rowspan=2 colspan=1>CombinedSites1,2,3</td><td rowspan=2 colspan=1></td><td rowspan=1 colspan=2>GTI PF4-Enhanced</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ZymutestIgGAM</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>17</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>153</td></tr><tr><td rowspan=1 colspan=2>Agreement</td><td rowspan=1 colspan=1>74%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Co-positivity</td><td rowspan=1 colspan=1>58%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Co-negativity</td><td rowspan=1 colspan=1>90%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Sample Size</td><td rowspan=1 colspan=1>345</td><td rowspan=1 colspan=1></td></tr></table>

In clinical studies, Zymutest IgG was compared with Seritonin Release Assay (SRA) for $n = 1 7 4$ samples. Matches indicate that both were positive or both were negative.

<table><tr><td># Matches</td><td>131</td></tr><tr><td>% Matching</td><td>75.29</td></tr></table>

In clinical studies, Zymutest IgG was compared with Asserachrom for $\mathtt { n } = 2 4 3$ samples.

<table><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Asserachrom</td></tr><tr><td rowspan=1 colspan=1>Sites 1 &amp;2</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ZymutestIgG</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>17</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>151</td></tr><tr><td rowspan=1 colspan=2>Agreement</td><td rowspan=1 colspan=1>76%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Co-positivity</td><td rowspan=1 colspan=1>44%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Co-negativity</td><td rowspan=1 colspan=1>90%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Sample Size</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1></td></tr></table>

# Reproducibility

Intra-assay: ZYMUTEST HIA Ig G and ZYMUTEST Ig GAM were tested on vials of positive control, in duplicate, taken at random from the lot.

<table><tr><td rowspan=1 colspan=1>Positive control</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Mean A450</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Anti PF4-IgG lot 061027D</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>3.07</td></tr><tr><td rowspan=1 colspan=1>Anti PF4 IgG lot 061214A</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>4.46</td></tr><tr><td rowspan=1 colspan=1>Anti PF4 IgGAM lot 061214D</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1.74</td><td rowspan=1 colspan=1>4.75</td></tr></table>

The reproducibility for Intra assay precision for the positive control was performed. The CVs are below $10 \%$ , in compliance with the specifications, and confirm an excellent homogeneity for the intra assay.

# Inter assay $\boldsymbol { : }$ Tested on one vial of positive control :

<table><tr><td rowspan=1 colspan=1>Positive control</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Mean A450</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Anti PF4-IgG lot 061027D</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>1.34</td><td rowspan=1 colspan=1>7.11</td></tr><tr><td rowspan=1 colspan=1>Anti PF4-IgGAM lot 061027G</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>7.50</td></tr></table>

The inter assay for all of the positive control results are in compliance with the specifications (CV below $10 \%$ .

# Conclusion

Based on comparison with the legally marketed PF 4 Enhanced and Asserachrom devices, the data demonstrates that ZYMUTEST HIA Ig G and ZYMUTEST HIA Ig GAM devices perform as well as the predicate device and they do not present new issues of safety and effectiveness. The Intra and inter assay reproducibility of the devices (ZYMUTEST HIA Ig G.and ZYMUTEST HIA Ig GAM) is within $10 \%$ CV.

Hyphen BioMed C/O Ola Anderson Aniara Corporation 6560 Gove Court Mason, Ohio 45040

Re: k071255 Trade/Device Name: Zymutest HIA IgG and Zymutest HIA IgGAM Regulation Number: 21 CFR 864.7695 Regulation Name: Platelet Factor 4 Radioimmunoassay Regulatory Class: Class II Product Code: LCO Dated: April 30, 2007 Received: May 10, 2007

Dear Mr. Anderson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number   
(800) 638-2041 or (240) 276-3150 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

KobrtBock

Robert L. Becker, M.D., Ph.D.   
Director   
Division of Immunology and Hematology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# Indication for Use Statement

510(k) Number: 071255

Device Name: ZYMUTEST HIA IgG and IgGAM

# Indications for use:

ZYMUTEST HIA IgG and IgGAM kits are designed as a solid phase enzyme- linked immunosorbent assay (ELISA). These products are intended to be used as an in vitro diagnostics kit by Hematology, coagulation or other pathology laboratories to assist in screening patients samples for the presence of heparin- associated antibodies commonly found in patients with heparin induced thrombocytopenia or thrombosis (HIT).

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

![](images/1c511cee462473fe17016d018270ccb3279a5966b0218d4a5bcd1ff1e7438aec.jpg)  
Page 1 of 1